|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-9-22
|
|
pubmed:abstractText |
The aim of this study was to evaluate the effect of levosimendan on mortality in cardiogenic shock (CS) after ST elevation myocardial infarction (STEMI).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1178-2048
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
657-63
|
|
pubmed:meshHeading |
pubmed-meshheading:20859537-Age Factors,
pubmed-meshheading:20859537-Aged,
pubmed-meshheading:20859537-Atrial Fibrillation,
pubmed-meshheading:20859537-Cardiotonic Agents,
pubmed-meshheading:20859537-Chi-Square Distribution,
pubmed-meshheading:20859537-Cohort Studies,
pubmed-meshheading:20859537-Electrocardiography,
pubmed-meshheading:20859537-Female,
pubmed-meshheading:20859537-Heart Arrest,
pubmed-meshheading:20859537-Humans,
pubmed-meshheading:20859537-Hydrazones,
pubmed-meshheading:20859537-Length of Stay,
pubmed-meshheading:20859537-Male,
pubmed-meshheading:20859537-Myocardial Infarction,
pubmed-meshheading:20859537-Myocardial Revascularization,
pubmed-meshheading:20859537-Proportional Hazards Models,
pubmed-meshheading:20859537-Pyridazines,
pubmed-meshheading:20859537-Sex Factors,
pubmed-meshheading:20859537-Shock, Cardiogenic,
pubmed-meshheading:20859537-Statistics, Nonparametric
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
|
|
pubmed:affiliation |
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. elmir@wlab.gu.se
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
